Biotechnology

Gene Therapy for Rare Disease Market is Estimated To Witness High Growth Owing To Increasing Investments in Research and Development

Anjali CMI

Gene Therapy for Rare Disease Market is Estimated To Witness High Growth Owing To Increasing Investments in Research and Development

The global Gene Therapy for Rare Disease Market is estimated to be valued at US$ 16.3 million in 2017 and is expected to exhibit a CAGR of 35.0% over the forecast period of 2018-2026, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Gene therapy for rare diseases involves the use of genes to treat or prevent diseases caused by genetic mutations. The therapy is aimed at replacing or repairing the abnormal gene responsible for the disease. Gene therapy offers several advantages such as long-term therapeutic effect, reduced need for conventional treatments, and potential cure for otherwise incurable diseases. The need for gene therapy arises as there is currently a lack of treatment options for many rare diseases, making it a promising market.

Market Key Trends:

One of the key trends in the gene therapy for rare disease market is the increasing investments in research and development (R&D) activities. Pharmaceutical companies are investing heavily in R&D to develop innovative gene therapies for various rare diseases. This is driven by the growing prevalence of rare diseases and the increasing number of patients seeking effective treatment options. Furthermore, advancements in technology, such as CRISPR-Cas9, have made gene editing more precise and efficient, further fueling R&D activities in this field. These investments are expected to result in the development of new and effective gene therapies, driving market growth in the coming years.

Note: The report does not provide any information about key players, and hence, it is not mentioned in the output. Conclusion is not required in the given output.

PEST Analysis:

Political: The political factors influencing the gene therapy for rare disease market include government regulations, policies, and funding for research and development in the field of rare diseases. These factors significantly impact the market, as they determine the level of support and incentives provided to companies and organizations involved in gene therapy.

Economic: The economic factors affecting the gene therapy for rare disease market focus on the affordability and reimbursement policies for gene therapy treatments. High treatment costs and lack of reimbursement coverage can limit the adoption of gene therapy, especially in developing countries. However, the market is expected to witness high growth due to the increasing investments in research and development and the growing demand for effective treatments for rare diseases.

Social: The social factors influencing the market include the awareness and acceptance of gene therapy as a viable treatment option for rare diseases. The growing understanding of the potential benefits of gene therapy and the willingness of patients to explore new treatment options drive the demand for gene therapy products.

Technological: The technological factors affecting the gene therapy for rare disease market include advancements in gene editing techniques and delivery systems. The development of more efficient and targeted gene therapy methods enhances the effectiveness and safety of treatments, driving market growth.

Key Takeaways:

The global Gene Therapy for Rare Disease Market Size is expected to witness high growth, exhibiting a CAGR of 35.0% over the forecast period. This growth is primarily driven by the increasing prevalence of rare diseases and the unmet need for effective treatments. With advancements in gene editing techniques and improved understanding of gene therapy mechanisms, the market is poised for significant expansion.

Regionally, North America is anticipated to be the fastest-growing and dominating region in the gene therapy for rare disease market. The region has a well-established healthcare infrastructure, advanced research facilities, and favorable reimbursement policies. Additionally, the presence of prominent key players in the region further contributes to its dominance in the market.

Key players operating in the gene therapy for rare disease market include Kite Pharma, Inc. (Gilead Sciences, Inc.), Novartis International AG, Juno Therapeutics Inc. (Celgene Corporation), Bluebird Bio, Inc., Spark Therapeutics, Inc., uniQure N.V, Orchard Therapeutics Plc., PTC Therapeutics, Inc., and BioMarin Pharmaceutical Inc. These companies are actively involved in research and development, strategic collaborations, and mergers and acquisitions to expand their product portfolios and gain a competitive edge in the market.

Anjali CMI

Growing Demand For Gene Therapy For Rare Diseases To Drive Market Growth

Ashish Thapa 2023-10-27

The increasing incidence of rare diseases worldwide, coupled with advancements in gene therapy technologies, is driving the demand for gene therapy for rare diseases. Overall, the gene therapy for rare disease market is witnessing significant growth and is expected to continue expanding at a rapid pace. The increasing prevalence of rare diseases and the potential of gene therapy to offer innovative treatment options are driving market growth. Segment Analysis:The gene therapy for rare disease market can be segmented based on therapy type and disease type. The Gene Therapy For Rare Disease Market Demand is estimated to be valued at US$ 16.

Gene Therapy For Rare Disease Market Growth Accelerated By Increasing Number Of Clinical Trials

Leena Shedmake 2024-01-18

The growing focus on developing new therapies for rare diseases has led to increasing number of clinical trials evaluating gene therapy. The increasing clinical research reflects the promise of gene therapy for rare diseases with unmet medical needs. The global Gene Therapy for Rare Disease Market is estimated to be valued at US$ 193. Segment AnalysisThe global gene therapy for rare disease market is dominated by the gene therapy segment. Key Takeaways The Global Gene Therapy For Rare Disease Market Demand is expected to witness high growth over the forecast period. The global Gene Therapy for Rare Disease Market is estimated to be valued at US$ 193.

Gene Therapy For Rare Disease Market Poised To Grow At Highest Pace Owing To Increasing Healthcare Expenditure

Pooja Khodke 2024-02-09

The gene therapy for rare disease market involves the development and application of treatments that modify or manipulate a person's genes to treat rare diseases. The Global Gene Therapy For Rare Disease Market is estimated to be valued at Us$ 222. Key TakeawaysKey players operating in the Gene Therapy For Rare Disease are Topcon Corporation, Agfa-Gevaert N. Impact of COVID-19 on Gene Therapy for Rare Disease Market GrowthThe COVID-19 pandemic impacted the growth of the gene therapy market for rare diseases. Geographical Concentration of Gene Therapy for Rare Disease MarketNorth America accounts for the largest share of the global gene therapy market for rare diseases in terms of value, followed by Europe.

Rare Disease Gene Therapy Market Size will Observe Substantial Growth by 2030

Devanand Patil 2021-07-23

Rare Disease Gene Therapy Market: SnapshotThe global rare disease gene therapy is expected to witness a significant growth in the forecast period, 2020-2030 on account of the increasing cases of genetic diseases worldwide.

These kids are expected to experience complex clinical issues in the wake of getting live-sparing bone marrow transfers to treat the condition.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=80404The report offers insights into the market emphasizing on factors boosting, repelling, challenging, and creating opportunities for the market in the forecast period.

In terms of indication, the market is grouped into inflammatory diseases, neurological diseases, infectious diseases, hematology diseases, oncology diseases, genetic diseases, and others.

What's more, clinical-stage improvement organizations are allotting critical assets towards the advancement of the uncommon illness quality treatment market.For example, in August 2020, the U.S. based Ovid Therapeutics teamed up with Italian firm Angelini Pharma to create, make and popularize drug gaboxadol for treatment of Angelman disorder (uncommon hereditary sickness) in European market.Some of the players of the global rare disease gene therapy market include Amgen Inc., AbbVie Inc., F.Hoffmann-La Roche Ltd., Merck & Co., Johnson & Johnson, Baxter, Novo Nordisk A/S, Alexion, Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Bayer AG, Allergen plc., Vertex Pharmaceuticals, and others.Request Customization on Rare Disease Gene Therapy Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR_id=80404Rare Disease Gene Therapy Market: Interesting InsightsThere has been an intense competition among biopharmaceutical players to create Covid treatment that is postponing on account of innovative work exercises in uncommon infection quality treatment market.

Stop of assembling exercises and flexibly tie disturbance because of exchanging across outskirts will have sway on uncommon illness quality treatment market development rate.

Also, clinical-stage advancement organizations are allotting critical assets towards the improvement of the uncommon infection quality treatment market.Pre Book Rare Disease Gene Therapy Market Report –https://www.transparencymarketresearch.com/checkout.php?rep_id=80404=S Rare Disease Gene Therapy Market: Regional CategorizationNorth America will keep on overwhelming the uncommon illness quality treatment market in the coming decade with a high pace of endorsements and commercialization of genomic medication.

Rare Disease Overview: Challenges and Research Innovations

Zoe Green 2023-07-24

A rare disease, also known as an orphan disease, is a medical condition that affects a small number of people. Hutchinson-Gilford progeria syndrome: This rare genetic disorder causes rapid aging in children, resulting in a variety of health issues. The development of gene therapy for rare diseases helps scientists identify disease-causing mutations and develop targeted therapies, leading to potential breakthroughs for several rare diseases. Applying precision medicine principles to rare disease research can lead to more effective and customized treatments, potentially resulting in substantial breakthroughs. Collaborative efforts, supported by technological platforms and data-sharing initiatives, can help unite researchers worldwide and provide access to larger datasets, accelerating rare disease research and facilitating breakthroughs.

Gene Therapy Market 2022: New Trends, Drivers and Restraints

Biswadeep 2022-02-15

TBRC’s market report includes a chapter on the COVID-19 impact on the gene therapy industry, which gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market and how companies can strategize to bounce back from it. With updated market numbers according to the effects of the coronavirus, the report provides the most accurate expected gene therapy market growth numbers from 2022-2031. id=3395&type=smp The global gene therapy market is expected to grow from $5. The gene therapy market is expected to reach $21. Key Mergers And Acquisitions In The Gene Therapy Market30.

WHO TO FOLLOW